Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck

J. Verweij; P. H M De Mulder; A. De Graeff; J. B. Vermorken; J. Wildiers; J. Kerger; J. Schornagel; F. Cognetti; A. Kirkpatrick; T. Sahmoud; J. L. Lefebvre

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck

J. Verweij, P. H M De Mulder, A. De Graeff, J. B. Vermorken, J. Wildiers, J. Kerger, J. Schornagel, F. Cognetti, A. Kirkpatrick, T. Sahmoud, J. L. Lefebvre

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma. Patients and methods: Patients with symptomatic and/or rapidly progressive metastatic or recurrent adenoid cystic carcinoma were eligible for this study. They were treated with mitoxantrone given intravenously by bolus injection at a dose of 14 mg/m², cycles repeated every 3 weeks. Results: Thirty-six chemotherapy-naive patients entered on trial, 4 were ineligible. A median of 6 cycles per patient were given. Leucocytopenia (in 97% of patients) was the most important side effect and tended to be cumulative. Other side effects were mainly mild to moderate and consisted of nausea (62%), vomiting (29%), alopecia (53%) and mucositis (41%). Four of 32 patients had a partial response (12%; 95% CI 4%-29%) lasting 3-13 months, 22 patients (69%) had a stable disease. Conclusion: Mitoxantrone at this dose and schedule has modest activity in adenoid cystic carcinomas.

Original language	English
Pages (from-to)	867-869
Number of pages	3
Journal	Annals of Oncology
Volume	7
Issue number	8
Publication status	Published - Oct 1996

Keywords

Adenoid cystic carcinoma
Mitoxantrone
Phase II study

ASJC Scopus subject areas

Oncology
Cancer Research

Fingerprint Dive into the research topics of 'Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck'. Together they form a unique fingerprint.

Cite this

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. / Verweij, J.; De Mulder, P. H M; De Graeff, A.; Vermorken, J. B.; Wildiers, J.; Kerger, J.; Schornagel, J.; Cognetti, F.; Kirkpatrick, A.; Sahmoud, T.; Lefebvre, J. L.

In: Annals of Oncology, Vol. 7, No. 8, 10.1996, p. 867-869.

Research output: Contribution to journal › Article › peer-review

@article{f302f54135a3405c9930feabe7f6ffdd,

title = "Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck",

abstract = "Background: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma. Patients and methods: Patients with symptomatic and/or rapidly progressive metastatic or recurrent adenoid cystic carcinoma were eligible for this study. They were treated with mitoxantrone given intravenously by bolus injection at a dose of 14 mg/m2, cycles repeated every 3 weeks. Results: Thirty-six chemotherapy-naive patients entered on trial, 4 were ineligible. A median of 6 cycles per patient were given. Leucocytopenia (in 97% of patients) was the most important side effect and tended to be cumulative. Other side effects were mainly mild to moderate and consisted of nausea (62%), vomiting (29%), alopecia (53%) and mucositis (41%). Four of 32 patients had a partial response (12%; 95% CI 4%-29%) lasting 3-13 months, 22 patients (69%) had a stable disease. Conclusion: Mitoxantrone at this dose and schedule has modest activity in adenoid cystic carcinomas.",

keywords = "Adenoid cystic carcinoma, Mitoxantrone, Phase II study",

author = "J. Verweij and {De Mulder}, {P. H M} and {De Graeff}, A. and Vermorken, {J. B.} and J. Wildiers and J. Kerger and J. Schornagel and F. Cognetti and A. Kirkpatrick and T. Sahmoud and Lefebvre, {J. L.}",

year = "1996",

month = oct,

language = "English",

volume = "7",

pages = "867--869",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "8",

}

TY - JOUR

T1 - Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck

AU - Verweij, J.

AU - De Mulder, P. H M

AU - De Graeff, A.

AU - Vermorken, J. B.

AU - Wildiers, J.

AU - Kerger, J.

AU - Schornagel, J.

AU - Cognetti, F.

AU - Kirkpatrick, A.

AU - Sahmoud, T.

AU - Lefebvre, J. L.

PY - 1996/10

Y1 - 1996/10

N2 - Background: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma. Patients and methods: Patients with symptomatic and/or rapidly progressive metastatic or recurrent adenoid cystic carcinoma were eligible for this study. They were treated with mitoxantrone given intravenously by bolus injection at a dose of 14 mg/m2, cycles repeated every 3 weeks. Results: Thirty-six chemotherapy-naive patients entered on trial, 4 were ineligible. A median of 6 cycles per patient were given. Leucocytopenia (in 97% of patients) was the most important side effect and tended to be cumulative. Other side effects were mainly mild to moderate and consisted of nausea (62%), vomiting (29%), alopecia (53%) and mucositis (41%). Four of 32 patients had a partial response (12%; 95% CI 4%-29%) lasting 3-13 months, 22 patients (69%) had a stable disease. Conclusion: Mitoxantrone at this dose and schedule has modest activity in adenoid cystic carcinomas.

AB - Background: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma. Patients and methods: Patients with symptomatic and/or rapidly progressive metastatic or recurrent adenoid cystic carcinoma were eligible for this study. They were treated with mitoxantrone given intravenously by bolus injection at a dose of 14 mg/m2, cycles repeated every 3 weeks. Results: Thirty-six chemotherapy-naive patients entered on trial, 4 were ineligible. A median of 6 cycles per patient were given. Leucocytopenia (in 97% of patients) was the most important side effect and tended to be cumulative. Other side effects were mainly mild to moderate and consisted of nausea (62%), vomiting (29%), alopecia (53%) and mucositis (41%). Four of 32 patients had a partial response (12%; 95% CI 4%-29%) lasting 3-13 months, 22 patients (69%) had a stable disease. Conclusion: Mitoxantrone at this dose and schedule has modest activity in adenoid cystic carcinomas.

KW - Adenoid cystic carcinoma

KW - Mitoxantrone

KW - Phase II study

UR - http://www.scopus.com/inward/record.url?scp=10244246633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10244246633&partnerID=8YFLogxK

M3 - Article

C2 - 8922205

AN - SCOPUS:10244246633

VL - 7

SP - 867

EP - 869

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -